Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

Pfizer just raised its dividend by 2.4% to $0.43, giving investors something to cheer about despite the stock’s lackluster ...

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with ongoing Seagen ...

A “discreet” new form of Viagra which dissolves on the tongue is likely to arrive in Britain within the next five years ...

After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.

The little blue pill has been used to treat erectile dysfunction for the past 25 years, but it may soon be replaced with a ...

Pharmaceutical giant Pfizer has recorded 11.4 billion dollars in profit from its Dutch subsidiary, C.P. Pharmaceuticals ...

US company Viatris has developed a new form of Viagra that could soon be hitting UK shelves in a game-changing development ...

Goldman Sachs projects Pfizer’s 2025 EPS at $3.13, beating consensus of $2.89. Paxlovid sales expected to reach $4.3 billion vs. consensus of $3.7 billion; Vyndaqel forecast misses. Pfizer Inc.

What we can glean from the pattern of accidental discoveries in science, especially in the pharmaceutical industry, and their ...